Renal Cell Carcinoma (RCC) Clinical Trials

Find Renal Cell Carcinoma (RCC) Clinical Trials Near You

Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

This study aims to develop and validate a contrast-enhanced CT-based deep-learning model for automatic and accurate preoperative discrimination between T1-T2 and T3 renal cell carcinoma. By quantifying the model's diagnostic performance on an independent test set-using AUC, sensitivity, specificity, positive/negative predictive values, and decision-curve analysis-we will establish a decision-support tool that can be seamlessly integrated into clinical PACS, thereby reducing staging errors, refining surgical planning, and improving patient outcomes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: t
View:

• Histopathologically confirmed renal cell carcinoma on postoperative specimen.

• Preoperative contrast-enhanced CT performed at our institution with slice thickness ≤ 1 mm and complete DICOM datasets.

• Postoperative pathologic staging clearly defined as pT1a-T2b or pT3a.

• CT image quality deemed adequate for analysis.

Locations
Other Locations
China
Peking University First Hospital, Beijing,
RECRUITING
Beijing
Contact Information
Primary
Zejin Ou
2411210230@bjmu.edu.cn
159 1494 4390
Time Frame
Start Date: 2024-09-01
Estimated Completion Date: 2027-12-01
Participants
Target number of participants: 1000
Related Therapeutic Areas
Sponsors
Leads: Peking University First Hospital

This content was sourced from clinicaltrials.gov